Barclays
PTHS

Barclays’s Pelthos Therapeutics PTHS Stock Holding History

Barclays’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$77 – 5599
2025
Q1 		$77 Buy
+5
New +$86 ﹤0.01% 5134

Other funds holding PTHS

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays's PTHS Position: Q2 2025 in Review

Barclays sold out of Pelthos Therapeutics (PTHS) in Q2 2025, closing a stake of 5 shares — an estimated $77 sold.

Barclays first reported a position in PTHS in Q1 2025 and held it in 1 quarter. The position peaked at $77 in Q1 2025. 5 funds tracked by Wall St. Rank hold PTHS as of Q2 2025.

  • Barclays reported no remaining Pelthos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 5 Pelthos Therapeutics shares in Q2 2025, an estimated $77.
  • Barclays first reported a position in Pelthos Therapeutics in Q1 2025 and held it in 1 quarter.
  • Barclays's Pelthos Therapeutics position peaked at $77 in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.